Commvault Systems Inc vs Edwards Lifesciences Corporation Common Stock — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.23B), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 7.9× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| CVLT | EW | |
|---|---|---|
Market Cap | $6.23B | $49.44B |
Volume | 720,354 | 3,508,027 |
Sector | Technology | Health |
52-Week High | $176.52 | $95.18 |
52-Week Low | $75.18 | $72.65 |
Typical Hold Time | 17 Days | — |
Enterprise Value | $6.22B | $45.90B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust revenue growth, with 2026 projections reaching $1.2 billion, though net income margins are expected to compress. Recent positive developments include AWS competency achievements and new board appointments, while analyst consensus remains strongly bullish with a $156.55 price target.
CVLT presents a compelling growth story with consistent earnings beats and expanding enterprise partnerships, but faces valuation concerns with elevated P/E and P/B ratios. The stock's upside potential is supported by strong institutional buying and positive technical momentum, though investors should monitor margin pressures and competitive threats in the data resilience space.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →